Leucadia Therapeutics


A New Vision

For the past 25 years most Alzheimer's disease research has viewed plaques and tangles pathology as the Cause of this disease, which has led to an unbroken string of failed clinical trials.    

LEUCADIA'S research has shown that plaques and tangles are the Effect of a more serious underlying condition that triggers the formation of those pathological features. 


Follow Up

Leucadia Therapeutics has a novel approach to treating Alzheimer's disease. 

Get in touch with us ▸


Restoring the Flow

Cerebrospinal fluid (CSF) clears toxic metabolites from intercellular spaces in the brain, much as the lymphatic system does in the rest of the body.  The first regions of the brain to be impacted by Alzheimer's disease are cleared by CSF that drains across a porous bone called the cribriform plate.  Aging and life events can occlude the cribriform plate and reduce the CSF-mediated clearance of toxic metabolites from those regions of the brain, thereby causing plaques and tangles formation.  

Leucadia’s patented Arethusta® technology restores CSF flow across the cribriform plate, improving the clearance of toxic metabolites from the earliest regions of the brain to be affected by Alzheimer's disease.


The cribriform plate is a highly complex porous bony structure that becomes occluded as we age. At Leucadia we have patented innovative interventions based on discoveries of previously unknown facets of the brain clearance system.